Brominated Vegetable Oil vs Tertiary Butylhydroquinone: which is worse?

What is Brominated Vegetable Oil?

Brominated vegetable oil (BVO) is a food additive created by bonding bromine atoms to vegetable oil (typically soybean oil), creating a denser-than-water compound. When added to citrus-flavored beverages, BVO acts as an emulsifier and weighting agent, keeping citrus flavor oils evenly distributed throughout the drink rather than floating to the surface.

What is Tertiary Butylhydroquinone?

Tertiary butylhydroquinone (TBHQ) is a synthetic phenolic antioxidant preservative derived from butane. It is one of the most potent antioxidants for polyunsaturated fats and oils and is commonly used in fast-food frying oils. Its chemical formula is C10H14O2.

Documented risks

Brominated Vegetable Oil: BVO's health concerns center on bromine accumulation in body fat and tissues. Bromine is a halogen related to iodine, and it competes with iodine in the body, potentially disrupting thyroid function—a critical concern since iodine is essential for thyroid hormone synthesis. The FDA-NIH collaborative research directly triggering the 2024 ban found adverse cardiac and thyroid effects in animal studies. This FDA-NIH work, published around 2022–2023, showed effects at dose levels closer to realistic human exposure than previous studies, removing the basis for BVO's safety determination under the Federal Food, Drug, and Cosmetic Act's 'reasonable certainty of no harm' standard. Historical case reports of human toxicity from excessive BVO consumption document bromoderma (skin lesions), memory loss, nerve damage, tremors, and fatigue in individuals consuming large volumes of BVO-containing beverages daily. Two well-documented US cases from the 1970s and 1980s involved bromism (bromine toxicity) from chronic overconsumption. Bromine bioaccumulates in fatty tissues. Long-term sub-clinical accumulation was a concern even before the FDA ban, particularly for heavy consumers of citrus sodas. The EU, Japan, and other countries banned BVO decades ago, making the US one of the last major markets to revoke approval. The FDA issued a proposed rule in November 2023 and a final rule on July 3, 2024, effective August 2, 2024, with compliance deadline August 2, 2025, after which BVO-containing products may not be manufactured for US sale.

Tertiary Butylhydroquinone: At high doses in animal studies, TBHQ has been shown to cause precancerous stomach lesions (squamous cell hyperplasia) in female rats. A study in Food and Chemical Toxicology documented these dose-dependent precancerous changes. The FDA limits TBHQ to 0.02% of fat content, reflecting dose-dependent safety thresholds. Immune function concerns emerged from research published around 2019-2020. A study (Farouk Musa and colleagues) found that TBHQ impaired the adaptive immune response to influenza in mouse models, including reduced effectiveness of influenza vaccination. EWG highlighted this research in its analysis. These findings have not been confirmed in human clinical trials but raised new dimensions of concern beyond cancer. Neurotoxicity: animal studies have documented TBHQ can cause precursors to certain types of cell injury in neural tissue at high doses, though effects at typical dietary exposure are not established. Allergic reactions including urticaria and contact dermatitis from TBHQ-containing cosmetics and personal care products are documented in dermatology literature. Japan banned TBHQ for food use. The EU restricts it in baby food (completely banned) and in adult food categories with maximum permitted levels. Australia and the UK restrict it.